Mouse Monoclonal PI 3 Kinase p85 alpha antibody. Suitable for WB, ICC/IF, IHC-P and reacts with Human samples. Cited in 177 publications. Immunogen corresponding to Recombinant Fragment Protein within Human PIK3R1.
Preservative: 0.05% Sodium azide
Constituents: 50% Glycerol (glycerin, glycerine), 49% PBS, 0.1% BSA
WB | ICC/IF | IHC-P | |
---|---|---|---|
Human | Tested | Tested | Tested |
Mouse | Predicted | Predicted | Predicted |
Rat | Predicted | Predicted | Predicted |
Chicken | Predicted | Predicted | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Chicken | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Chicken | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 5 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Chicken | Dilution info - | Notes - |
Select an associated product type
Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF, KIT, PDGFRA and PDGFRB. Likewise, plays a role in ITGB2 signaling (PubMed:17626883, PubMed:19805105, PubMed:7518429). Modulates the cellular response to ER stress by promoting nuclear translocation of XBP1 isoform 2 in a ER stress- and/or insulin-dependent manner during metabolic overloading in the liver and hence plays a role in glucose tolerance improvement (PubMed:20348923).
GRB1, PIK3R1, Phosphatidylinositol 3-kinase regulatory subunit alpha, PI3-kinase regulatory subunit alpha, PI3K regulatory subunit alpha, PtdIns-3-kinase regulatory subunit alpha, Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha, PI3-kinase subunit p85-alpha, PtdIns-3-kinase regulatory subunit p85-alpha
Mouse Monoclonal PI 3 Kinase p85 alpha antibody. Suitable for WB, ICC/IF, IHC-P and reacts with Human samples. Cited in 177 publications. Immunogen corresponding to Recombinant Fragment Protein within Human PIK3R1.
Preservative: 0.05% Sodium azide
Constituents: 50% Glycerol (glycerin, glycerine), 49% PBS, 0.1% BSA
Phosphoinositide 3-kinase (PI3K) phosphorylates phosphatidylinositol (PI), PI-4-phosphate and PI-4,5-bisphosphate to catalyze the production of PI-3,4,5-triphosphate. Growth factors and hormones activate PI 3 Kinase to coordinate various cellular events, such as cell growth, cell cycle entry, cell migration and cell survival.
PI 3 Kinase p85 alpha also known as PI3KR1 or phospho PI3K is a regulatory subunit of phosphoinositide 3-kinase (PI3K) that plays a fundamental role in various signaling pathways. The p85 protein has a molecular weight of approximately 85 kDa. This protein is widely expressed in many cell types facilitating essential cellular functions by forming a heterodimer with the class I PI3K catalytic subunit often implicated in regulating lipid signaling pathways.
P85 alpha modulates intracellular signaling by interacting with other proteins in a complex formation with catalytic subunit p110. This interaction enables the initiation of downstream signaling cascades controlling cell growth proliferation and survival. PI 3 kinase activity mediated by p85 alpha is integral to cellular homeostasis and metabolism helping to execute cellular responses to a variety of growth factors and hormones.
PI 3 Kinase p85 alpha integrates into two principal signaling networks: the PI3K-Akt and mTOR pathways. These pathways are instrumental for regulating anabolic processes and cell survival. The p85 form of PI3K interacts with additional proteins such as Akt and mTOR coordinating cellular energy balance promoting protein synthesis and inhibiting apoptosis. Through these interactions the protein ensures that cells respond accurately to nutritional and stress signals.
Alterations in PI 3 Kinase p85 alpha function have been linked to cancer and type 2 diabetes. Aberrant signaling involving PI3K-Akt-mTOR pathways due to mutations in PI3KR1 can contribute to tumor progression and chemoresistance. Moreover dysfunction of this pathway affects insulin signaling connecting p85 alpha to diabetic pathologies. Proteins such as IRS-1 (insulin receptor substrate 1) act alongside p85 alpha in mediating these disease-associated processes emphasizing its importance in maintaining physiological balance.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Lane 1: Western blot - Anti-PI 3 Kinase p85 alpha antibody [M253] (ab86714) at 1/1000 dilution
Lane 2: Western blot - Anti-PI 3 Kinase p85 alpha antibody [M253] (ab86714) at 1/2000 dilution
Lane 3: Western blot - Anti-PI 3 Kinase p85 alpha antibody [M253] (ab86714) at 1/4000 dilution
All lanes: A431 cell lysate
Predicted band size: 83 kDa
Observed band size: 85 kDa
Immunocytochemical labeling of PI 3 Kinase p85 in aldehyde-fixed and NP-40-permeabilized A431 cells. The cells were labeled with ab86714, then the antibody was detected using appropriate secondary antibody conjugated to DyLight® 594.
IHC image of PI 3 Kinase p85 staining in Human skeletal muscle formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (100x Citrate Buffer pH 6.0 ab64236) (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab86714, 5μg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
ICC/IF image of ab86714 stained SKNSH cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum (Normal Goat Serum ab7481) / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab86714, 5μg/ml) overnight at +4°C. The secondary antibody (green) was Goat Anti-Mouse IgG H&L (DyLight® 488) preadsorbed ab96879, DyLight® 488 goat anti-mouse IgG (H+L) (Goat Anti-Mouse IgG H&L (DyLight® 488) ab96871) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43μM.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com